Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. Announcements
  3. DRAFT - Creative Imagery Document Open for Consultation
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

DRAFT - Creative Imagery Document Open for Consultation

Scheduled Pinned Locked Moved Announcements
externalcreative imageryconsultation
1 Posts 1 Posters 895 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Jennifer CarrollJ Offline
    Jennifer CarrollJ Offline
    Jennifer Carroll
    wrote on last edited by
    #1

    Announcing PAAB's Draft Creative Imagery in Health Professional Directed Pharmaceutical Advertising

    @Manufacturer @Agency we are pleased to announce the release of the DRAFT Creative Imagery in Health Professional Directed Pharmaceutical Advertising, a culmination of dedicated efforts by the Creative Imagery Committee to support the development of creative within the pharmaceutical industry.

    Stakeholder Feedback Invited Until December 2nd
    The draft guidance document is now live and open for comments from all stakeholders until December 2nd. We highly encourage industry professionals, healthcare providers, and other interested parties to review the document and share their valuable feedback.
    How to Access and Comment
    • Access the Draft Document: HTML or PDF
    • Submit Your Feedback: Please send your comments to info@paab.ca

    Our aim is to finalize the guidance document by the end of 2024. This comprehensive resource will assist the industry in developing creative imagery that is both engaging and compliant with regulatory standards, ultimately enhancing the quality and credibility of pharmaceutical advertising.

    Next Steps After the Comment Period
    Following the conclusion of the comment period, the PAAB will consolidate all feedback and present it anonymously to the committee. This ensures an unbiased review process where every suggestion is considered equally. The committee will then deliberate on the feedback to make any necessary adjustments to the guidance document.

    Your insights are crucial in shaping a guidance document that reflects the needs and perspectives of all stakeholders. Together, we can foster an environment of innovation and compliance in pharmaceutical advertising.

    For any questions or additional information, please contact us at info@paab.ca.

    1 Reply Last reply
    0
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups